Medical Doctor Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Benjamin Hendricks

Neurological Surgery San Luis Obispo, CA Medical Doctor

NPI 1295180461 CMS profile 11454209

35 Casa St Ste 320, Ste 320, San Luis Obispo, CA 93405

Open in the dashboard

General payments

$202,354

116 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Benjamin Hendricks of San Luis Obispo, CA is reported in the CMS Open Payments database as having received $202,354 across 116 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,087 26
2024 General $162,997 63
2023 General $37,270 27

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Benjamin Hendricks
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Benjamin Hendricks were reported at $2,087. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Benjamin Hendricks Neurological Surgery median Middle half National median
2019 $0 $582 $138–$3,006 $163
2020 $0 $294 $76–$2,174 $114
2021 $0 $387 $105–$2,432 $132
2022 $0 $542 $139–$2,989 $149
2023 $37,270 $534 $145–$2,697 $160
2024 $162,997 $574 $155–$3,046 $164
2025 $2,087 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. Medtronic, Inc. $197,033 92 payments
  2. Alphatec Spine, Inc $3,983 8 payments
  3. Abbott Laboratories $845 7 payments
  4. Integra LifeSciences Corporation $171 2 payments
  5. Stryker Corporation $128 1 payment
  6. TissueTech, Inc. $56 2 payments
  7. Ceribell, Inc. $55 1 payment
  8. Cornerstone Medical Associates, Inc. $43 1 payment
  9. Ebi, LLC $20 1 payment
  10. AbbVie, Inc. $19 1 payment

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Consulting Fee $101,480 2 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $87,960 19 payments
  3. Travel and Lodging $9,835 42 payments
  4. Food and Beverage $3,079 53 payments
Products named General payments · program years 2023–2025
  1. STEALTHSTATION S8 PLATFORM $27,096 60 payments
  2. Other - Miscellaneous $3,951 6 payments
  3. MAZOR X SYSTEM $1,486 11 payments
  4. CD HORIZON SPINAL SYSTEM $852 3 payments
  5. INFINITY $736 2 payments
  6. UNID_PASS $236 1 payment
  7. CUSA CLARITY $171 2 payments
  8. DURASEAL EXACT SPINAL SEALANT SYSTEM $171 2 payments
  9. CODMAN HAKIM $171 2 payments
  10. CODMAN CERTAS $171 2 payments
  11. Other $715 12 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

183

Median for Neurosurgery: 83

Drug cost

$1,584

Median for Neurosurgery: $872

Branded share of claims

26.2%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ondansetron Odt Ondansetron Brand 36 $473
Oxycodone Hcl Generic 36 $401
Tizanidine Hcl Generic 64 $357
Gabapentin Generic 35 $242
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 12 $111

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 79 billing codes

Paid by Medicare

$161,855

Medicare's payments for the services billed

Medicare patients

219

Average age 73

Services billed

620

111 women, 108 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 72%
Ischemic heart disease 28%
Depression 28%
Diabetes 20%
Atrial fibrillation 19%
Osteoporosis 18%
Chronic kidney disease 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

116 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurological Surgery in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record